65 resultados para 920 Biography
Resumo:
HR212, a recombinant protein expressed in Escherichia coli, has been previously reported to inhibit HIV-1 membrane fusion at low nanomolar level. Here we report that HR212 is effective in blocking laboratory strain HIV-1IIIB entry and replication with EC50 values of 3.920.62 and 6.591.74 nM, respectively, and inhibiting infection by clinic isolate HIV-1KM018 with EC50 values of 44.4410.20 nM, as well as suppressing HIV-1- induced cytopathic effect with an EC50 value of 3.041.20 nM. It also inhibited HIV-2ROD and HIV-2CBL-20 entry and replication in the M range. Notably, HR212 was highly effective against T20-resistant strains with EC50 values ranging from 5.09 to 7.75 nM. Unlike T20, HR212 showed stability sufficient to inhibit syncytia formation in a time-of-addition assay, and was insensitive to proteinase K digestion. These results suggest that HR212 has great potential to be further developed as novel HIV-1 fusion inhibitor for treatment of HIV/ AIDS patients, particularly for those infected by T20-resistant variants.
Resumo:
(RF-MBE)(AlInGaN),AlAlInGaN,(RHEED).(SEM)(RBS)X(XRD)(CL)AlInGaN.:GaNAlInGaN,;920,AlInGaNAl/In4.7,X5arcmin,25nm,AlInGaN.
Resumo:
HIRFL,8055MeV/u~(12)C,000101nA,50mm7348%,8087%,Bragg13866mm,7171MeV/u,,HIRFL,,
Resumo:
3 3 .4MeV/u17N197Au , 1 7 ( 4 83) 1 4 ( 2 .3 9.0) .Z =3 6 . - ,17N
Resumo:
For the first time the physical properties of therapeutic carbon-ion beam supplied by, the shallow-seated tumor therapy terminal at the Heavy Ion Research Facility in Lanzhou (HIRFL) are measured. For a 80.55MeV/u C-12 ion beam delivered to the therapy terminal, the homogeneity of irradiation fields is 73.48%, when the beam intensity varied in the range of 0.001-0.1nA (i.e. 1 X 10(6) - 1 X 10(8) particles per second). The stability of the beam intensity within a few minutes is estimated to be 80.87%. The depth-dose distribution of the beam at the isocenter of the therapy facility is measured, and the position of the high-dose Bragg peak is found to be located at the water-equivalent depth of 13.866mm. Based on the relationship between beam energy and Bragg peak position, the corresponding beam energy at the isocenter of the therapy terminal is evaluated to be 71.71MeV/u for the original 80.55MeV/u C-12 ion beam, which consisted basically with calculation. The readout of the previously-used air-free ionization chamber regarding absorbed dose is calibrated as well in this experiment. The results indicate that the performance of the therapy facility should be optimized further to meet the requirements of clinical trial.
Resumo:
:,,0.788,0.470,0.7580.650,7.8,18.4,5.96.5m,1.857,1.881,1.9331.920Moran'sI(12m)0.4,,,
